AliExpress (速卖通) Signs MOU with Austrian Post to Enhance Local Logistics and Warehousing

Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors

Europe’s reindustrialization is creating new opportunities for Chinese companies. However, the winners will not necessarily be those seeking quick acquisitions or rapid market access. The real opportunities belong to companies capable of embedding themselves into Europe’s industrial ecosystem and supporting the long-term transformation of local industries.

SEALIEN ROBOTICS Raises Over CNY 500 Million as Overseas Deep-Sea Robot Orders Accelerate

SEALIEN ROBOTICS (深海智人), a Guangzhou-based developer of deep-sea industrial robots, announced on Aug. 13 that it had completed a Series A financing round exceeding CNY 500 million. The funding comes as the company secures several hundred million yuan in whole-unit robot contracts and expands across the Middle East, Europe, Southeast Asia and other overseas markets.

Blokees’ Overseas Revenue Surges 228.5% as Building Toys Gain Global Traction

Chinese building-toy company Blokees (布鲁可) reported on Aug. 12 that its overseas revenue reached CNY 366 million in the first half of 2026, up 228.5% year on year, as the company expanded its distribution and licensed-IP product portfolio across the Americas and Southeast Asia.

Phantom Blade Zero Becomes First Chinese Game to Receive a Dedicated Sony State of Play

Sony Interactive Entertainment announced on Aug. 11 that it will hold a dedicated State of Play presentation for Chinese action role-playing game Phantom Blade Zero (《影之刃零》) on Aug. 18. The 15-to-20-minute broadcast will focus entirely on the game, marking the first time Sony has organized a standalone State of Play showcase for a Chinese-developed title.

Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand

Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.